IP Library › Granted Patent US 10,842,753
Granted Patent B2
US 10,842,753 · App. 16/408,899 · Granted Nov 24, 2020

Modified alginates for cell encapsulation and cell therapy

Inventors: Arturo J. Vegas (Belmont, MA); Minglin Ma (Ithaca, NY); Kaitlin M. Bratlie (Ames, IA); Daniel G. Anderson (Framingham, MA); Robert S. Langer (Newton, MA)
Assignees: Massachusetts Institute of Technology; The Children's Medical Center Corporation
A61K9/5036A61K9/0024A61K35/39A61K45/06C08B37/0084A61K9/5161
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,842,753
App. No.
16/408,899
Granted
Nov 24, 2020
Kind
B2
Abstract

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

Claims (20)

1. A multiply modified alginate polymer which is selected from

2. The multiply modified alginate polymer of claim 1 , wherein more than 15% of the monomers in the modified alginate polymer are covalently modified monomers.

3. The multiply modified alginate polymer of claim 1 , which is

4. The multiply modified alginate polymer of claim 1 , which is

5. The multiply modified alginate polymer of claim 1 , which is

6. The multiply modified alginate polymer of claim 1 , which is

7. The multiply modified alginate polymer of claim 1 , which is

8. The multiply modified alginate polymer of claim 1 , which is

9. The multiply modified alginate polymer of claim 1 , which is

10. The multiply modified alginate polymer of claim 1 , which is

11. The multiply modified alginate polymer of claim 1 , which is

12. A hydrogel comprising a modified alginate according to claim 1 .

13. The hydrogel of claim 12 , comprising Ca 2+ , Ba 2+ , or Sr 2+ crosslinking the modified alginate polymer.

14. The hydrogel of claim 12 , wherein the multiply modified alginate polymer is

15. A capsule comprising a hydrogel according to claim 12 and having cells encapsulated therein.

16. The capsule of claim 15 , wherein the hydrogel further comprises an unmodified alginate.

17. The capsule of claim 16 , wherein the unmodified alginate has a weight average molecular weight of 50,000 to 250,000 Daltons.

18. The capsule of claim 15 , wherein the cells are genetically altered.

19. The capsule of claim 15 , wherein the cells are islet cells.

20. The capsule of claim 15 , wherein the multiply modified alginate polymer is

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2019
From: VEGAS, ARTURO J.; MA, MINGLIN; BRATLIE, KAITLIN M.; ANDERSON, DANIEL G.; LANGER, ROBERT S.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 050788/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2019
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY; THE CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 050788/0941 →
Continuity (5)
Continuation 15588481 · May 5, 2017
Continuation 15208192 · Jul 12, 2016
Continuation 13487524 · Jun 4, 2012
Provisional Application 61492705 · Jun 2, 2011
Related Publication 20190262272A1 · Aug 29, 2019
Cited By (2)
US 12,306,081 US 12,570,955